Loading…
Diagnostics company making molecular tests that monitor organ transplant patients for rejection risk.
Diagnostics company making molecular tests that monitor organ transplant patients for rejection risk.
Earns per test run in its own labs for transplant centres, billed mostly to Medicare and private insurers rather than to hospitals directly, so insurance coverage and per-test payment rates decide results. Kidney transplant monitoring is the core; heart tests came alongside.
Moat: narrow (IP / patents, data, regulatory licence). Patented, clinically validated transplant-rejection tests with deep transplant-center relationships.
Headquarters: Brisbane, California · Founded: 1998 · Employees: 765
Size CareDx (CDNA) is a United States Health Care company (Medical Specialties) with a market value of $4.13B, the 1328th largest of 3,117 United States companies the cockpit tracks. Shares closed at $78.56 on 6 Nov 2026.
Performance Over six months the shares gained 260.0%, against +6.2% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 38.9% over the last twelve months (peer median +4.0%); the operating margin is 0.9% (peer median 12.6%).
Valuation It trades at 53.2× forward earnings against a peer median of 20.2× (most expensive of 19).
Capital Return on invested capital runs 15.9 points below its cost of capital (17.3% WACC).
Short interest Short interest is 13.0% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $497M | $380M | $334M | $280M | $322M |
| Revenue growth | — | +14% | +19% | -13% | — |
| Gross profit | $351M | $254M | $222M | $176M | $207M |
| EBITDA | $28.0M | -$1.71M | -$33.5M | -$82.1M | -$61.2M |
| Net income | $129M | -$21.4M | $52.5M | -$190M | -$76.6M |
| Free cash flow | $59.8M | $36.1M | $31.6M | -$26.7M | -$46.5M |
| Capital expenditure | $9.26M | $6.59M | $6.48M | $9.24M | $24.3M |
| Total debt | $29.0M | $26.2M | $28.4M | $34.2M | $39.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CareDx CDNA | $4.13B | +260% | +39% | 1% | 53.2× | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -11% | n/a | n/a |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Eurofins Scientific ERF.PA | $17.5B | +49% | +3% | 12% | 23.0× | 13.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CDNA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.3% | +8.1% | highest of 21 |
| 6-month return | +260.0% | +6.2% | highest of 21 |
| Distance from 52-week high | -13.6% | -22.1% | 8th highest of 21 |
| Revenue growth (TTM) | +38.9% | +4.0% | 2nd highest of 20 |
| Operating margin | 0.9% | 12.6% | 4th lowest of 20 |
| Forward P/E | 53.2× | 20.2× | most expensive of 19 |
| ROIC minus cost of capital | -15.9 pp | -0.3 pp | lowest of 19 |
| Net debt / EBITDA | -7.9× | 1.1× | least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 14% | 17.8× | -5.3% | +11.3% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |
| ICU Medical ICUI | United States | $4.30B | +36% | -9% | 7% | 19.5× | 22.1% | +11.9% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |